Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 88

1.

Validation of a hypoxia-inducible factor-1 alpha specimen collection procedure and quantitative enzyme-linked immunosorbent assay in solid tumor tissues.

Park SR, Kinders RJ, Khin S, Hollingshead M, Antony S, Parchment RE, Tomaszewski JE, Kummar S, Doroshow JH.

Anal Biochem. 2014 Aug 15;459:1-11. doi: 10.1016/j.ab.2014.04.025. Epub 2014 May 4.

PMID:
24799347
[PubMed - in process]
2.

Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma.

Yavuz S, Apolo AB, Kummar S, Del Rivero J, Madan RA, Shawker T, Reynolds J, Celi FS.

Thyroid. 2014 Aug;24(8):1223-31. doi: 10.1089/thy.2013.0621. Epub 2014 Jun 5.

PMID:
24724719
[PubMed - in process]
3.

These tumors can be associated with known genetic syndromes, such as the von Hippel-Lindau or multiple endocrine neoplasia 2 syndromes, or they can arise sporadically. Foreword.

Kummar S.

Curr Probl Cancer. 2014 Jan-Feb;38(1):6. doi: 10.1016/j.currproblcancer.2014.02.001. Epub 2014 Feb 17. No abstract available.

PMID:
24636753
[PubMed - in process]
4.

Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors.

Jeong W, Rapisarda A, Park SR, Kinders RJ, Chen A, Melillo G, Turkbey B, Steinberg SM, Choyke P, Doroshow JH, Kummar S.

Cancer Chemother Pharmacol. 2014 Feb;73(2):343-8. doi: 10.1007/s00280-013-2362-z. Epub 2013 Nov 30.

PMID:
24292632
[PubMed - indexed for MEDLINE]
5.

Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors.

Jeong W, Park SR, Rapisarda A, Fer N, Kinders RJ, Chen A, Melillo G, Turkbey B, Steinberg SM, Choyke P, Doroshow JH, Kummar S.

Invest New Drugs. 2014 Apr;32(2):340-6. doi: 10.1007/s10637-013-0048-3. Epub 2013 Nov 16.

PMID:
24242862
[PubMed - in process]
6.

Current Problems in Cancer. Bone tumors in children and young adults. Foreword.

Kummar S.

Curr Probl Cancer. 2013 Jul-Aug;37(4):159. doi: 10.1016/j.currproblcancer.2013.07.001. No abstract available.

PMID:
24238579
[PubMed - indexed for MEDLINE]
7.

Wee1 kinase as a target for cancer therapy.

Do K, Doroshow JH, Kummar S.

Cell Cycle. 2013 Oct 1;12(19):3159-64. doi: 10.4161/cc.26062. Epub 2013 Aug 26. Review.

PMID:
24013427
[PubMed - indexed for MEDLINE]
8.

United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies.

Jeong W, Doroshow JH, Kummar S.

Curr Probl Cancer. 2013 May-Jun;37(3):110-44. doi: 10.1016/j.currproblcancer.2013.06.001. Review. No abstract available.

PMID:
23972982
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas.

Kummar S, Gutierrez ME, Anderson LW, Klecker RW Jr, Chen A, Murgo AJ, Doroshow JH, Collins JM.

Cancer Chemother Pharmacol. 2013 Oct;72(4):917-23. doi: 10.1007/s00280-013-2244-4. Epub 2013 Aug 3.

PMID:
23912694
[PubMed - indexed for MEDLINE]
10.

Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.

Shibata SI, Chung V, Synold TW, Longmate JA, Suttle AB, Ottesen LH, Lenz HJ, Kummar S, Harvey RD, Hamilton AL, O'Neil BH, Sarantopoulos J, LoRusso P, Rudek MA, Dowlati A, Mulkerin DL, Belani CP, Gandhi L, Lau SC, Ivy SP, Newman EM.

Clin Cancer Res. 2013 Jul 1;19(13):3631-9. doi: 10.1158/1078-0432.CCR-12-3214. Epub 2013 May 7.

PMID:
23653147
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

LC-MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma.

Kiesel BF, Parise RA, Tjørnelund J, Christensen MK, Loza E, Tawbi H, Chu E, Kummar S, Beumer JH.

J Pharm Biomed Anal. 2013 Jul-Aug;81-82:89-98. doi: 10.1016/j.jpba.2013.03.025. Epub 2013 Apr 9.

PMID:
23644904
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Cediranib for metastatic alveolar soft part sarcoma.

Kummar S, Allen D, Monks A, Polley EC, Hose CD, Ivy SP, Turkbey IB, Lawrence S, Kinders RJ, Choyke P, Simon R, Steinberg SM, Doroshow JH, Helman L.

J Clin Oncol. 2013 Jun 20;31(18):2296-302. doi: 10.1200/JCO.2012.47.4288. Epub 2013 Apr 29.

PMID:
23630200
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Molecular targets in cancer therapy.

Kummar S, Doroshow JH.

Expert Rev Anticancer Ther. 2013 Mar;13(3):267-9. doi: 10.1586/era.12.170.

PMID:
23477512
[PubMed - indexed for MEDLINE]
14.

A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas.

Park SR, Speranza G, Piekarz R, Wright JJ, Kinders RJ, Wang L, Pfister T, Trepel JB, Lee MJ, Alarcon S, Steinberg SM, Collins J, Doroshow JH, Kummar S.

Cancer Chemother Pharmacol. 2013 Apr;71(4):981-90. doi: 10.1007/s00280-013-2091-3. Epub 2013 Feb 13.

PMID:
23404627
[PubMed - indexed for MEDLINE]
15.

First-in-human phase 0 trial of oral 5-iodo-2-pyrimidinone-2'-deoxyribose in patients with advanced malignancies.

Kummar S, Anderson L, Hill K, Majerova E, Allen D, Horneffer Y, Ivy SP, Rubinstein L, Harris P, Doroshow JH, Collins JM.

Clin Cancer Res. 2013 Apr 1;19(7):1852-7. doi: 10.1158/1078-0432.CCR-12-3118. Epub 2013 Feb 12.

PMID:
23403637
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Safety and feasibility of targeted agent combinations in solid tumours.

Park SR, Davis M, Doroshow JH, Kummar S.

Nat Rev Clin Oncol. 2013 Mar;10(3):154-68. doi: 10.1038/nrclinonc.2012.245. Epub 2013 Jan 29. Review.

PMID:
23358316
[PubMed - indexed for MEDLINE]
17.

Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues.

Pfister TD, Hollingshead M, Kinders RJ, Zhang Y, Evrard YA, Ji J, Khin SA, Borgel S, Stotler H, Carter J, Divelbiss R, Kummar S, Pommier Y, Parchment RE, Tomaszewski JE, Doroshow JH.

PLoS One. 2012;7(12):e50494. doi: 10.1371/journal.pone.0050494. Epub 2012 Dec 28.

PMID:
23284638
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Antiangiogenic approaches for the treatment of advanced synovial sarcomas.

Do K, Doroshow JH, Kummar S.

Curr Opin Oncol. 2012 Jul;24(4):425-30. doi: 10.1097/CCO.0b013e328354c141. Review.

PMID:
22572725
[PubMed - indexed for MEDLINE]
19.

Advances in using PARP inhibitors to treat cancer.

Kummar S, Chen A, Parchment RE, Kinders RJ, Ji J, Tomaszewski JE, Doroshow JH.

BMC Med. 2012 Mar 9;10:25. doi: 10.1186/1741-7015-10-25. Review.

PMID:
22401667
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.

Rajan A, Carter CA, Kelly RJ, Gutierrez M, Kummar S, Szabo E, Yancey MA, Ji J, Mannargudi B, Woo S, Spencer S, Figg WD, Giaccone G.

Clin Cancer Res. 2012 Apr 15;18(8):2344-51. doi: 10.1158/1078-0432.CCR-11-2425. Epub 2012 Feb 27.

PMID:
22371451
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk